BAY59-7939, Dialysis Heamofiltration Study
The main objective of the study was to investigate the effect of hemodialysis on the pharmacokinetics (PK) maximum observed drug concentration in measured matrix after single dose administration (Cmax), Cmax divided by dose per body weight (Cmax,norm), area under the concentration versus time curve from zero to infinity after single (first) dose (AUC) and AUC divided by dose per body weight (AUCnorm)) of rivaroxaban (Xarelto / BAY59-7939) in subjects with end-stage renal disease (ESRD) on hemodialysis and age-, body weight-, and gender-matched healthy volunteers.
No Inclusion Criteria Available
No Exclusion Criteria Available
Kiel, Germany, 24105
E-mail: [email protected]
Phone: Not Available
Single dose, randomized, parallel-group study to investigate the pharmacokinetics and pharmacodynamics of rivaroxaban in patients undergoing hemodialysis in comparison to age-and gender-matched healthy volunteers